Cited 0 time in
Multicenter trial for safety and toxicity of a nanoparticle docetaxel formulation in breast cancer
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Kim, T. H. | - |
| dc.contributor.author | Gwak, G. | - |
| dc.contributor.author | Chung, M. S. | - |
| dc.contributor.author | Kim, J. I. | - |
| dc.contributor.author | Park, I. | - |
| dc.contributor.author | Um, E. | - |
| dc.contributor.author | Han, J. W. | - |
| dc.contributor.author | Lee, A. | - |
| dc.date.accessioned | 2021-09-27T06:19:30Z | - |
| dc.date.available | 2021-09-27T06:19:30Z | - |
| dc.date.created | 2021-08-31 | - |
| dc.date.issued | 2018-11-23 | - |
| dc.identifier.issn | 0923-7534 | - |
| dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/133120 | - |
| dc.language | 영어 | - |
| dc.language.iso | en | - |
| dc.publisher | OXFORD UNIV PRESS | - |
| dc.title | Multicenter trial for safety and toxicity of a nanoparticle docetaxel formulation in breast cancer | - |
| dc.type | Conference | - |
| dc.contributor.affiliatedAuthor | Chung, M. S. | - |
| dc.identifier.wosid | 000458082200068 | - |
| dc.identifier.bibliographicCitation | European-Society-for-Medical-Oncology Asia Congress | - |
| dc.relation.isPartOf | European-Society-for-Medical-Oncology Asia Congress | - |
| dc.relation.isPartOf | ANNALS OF ONCOLOGY | - |
| dc.citation.title | European-Society-for-Medical-Oncology Asia Congress | - |
| dc.citation.conferencePlace | SI | - |
| dc.citation.conferencePlace | Singapore, SINGAPORE | - |
| dc.citation.conferenceDate | 2018-11-23 | - |
| dc.type.rims | CONF | - |
| dc.description.journalClass | 1 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366
COPYRIGHT © 2024 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
